Erasca ERAS
NASDAQ ERAS
$16.13 -0.13 (-0.80%)
As of: Sep 4, 2026 · 1:36 PM EDT

Erasca (ERAS) Interest Expenses (2020 - 2026)

Erasca's (ERAS) quarterly Interest Expenses came in at $672.8 million in Q1 2026, up 44752.4% YoY from N/an in Q1 2025, and up 44752.4% on a QoQ basis from $1.5 million in Q4 2025.

Analysis

Erasca (ERAS) Interest Expenses (2020 - 2026) Analysis & Trends

Erasca (ERAS) has 7 years of Interest Expenses data on file, last reported at $672.8 million in Q1 2026.

  • Quarterly Interest Expenses rose 44752.4% year-over-year to $672.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $672.8 million (up 102658.84% YoY) and the FY2025 annual result came in at $242.2 million, up 1764.65% from the prior year.
  • Interest Expenses climbed to $672.8 million in Q1 2026, from $1.5 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $672.8 million in Q1 2026 to a low of -$4.5 million in Q4 2023.
  • A 5-year average of $65.5 million and a median of $16.7 million in 2024 frame the typical range for Interest Expenses.
  • Annual changes were most pronounced in 2023 — Interest Expenses tumbled 826.99% — and 2026, when it jumped 44752.4%.
  • Tracing ERAS's Interest Expenses over 5 years: stood at $615000.0 in 2022, then plunged by 826.99% to -$4.5 million in 2023, then jumped by 138.02% to $1.7 million in 2024, then dropped by 11.76% to $1.5 million in 2025, then jumped by 44752.4% to $672.8 million in 2026.
  • The last three Interest Expenses figures came in at $672.8 million (Q1 2026), $1.5 million (Q4 2025), and $16.5 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Expense (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn -
5 Revolution Medicines 44.05 Bn 44.05 Bn - 23.78 Mn
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - 93.62 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn 20.27 Mn
10 Erasca 5.02 Bn 5.02 Bn - 63,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 63,000.00
Jun 30, 2025 81,000.00
Mar 31, 2025 76,000.00
Jun 30, 2024 460,000.00
Mar 31, 2024 66,000.00
Dec 31, 2023 67,000.00
Sep 30, 2023 49,000.00
Jun 30, 2023 62,000.00
Mar 31, 2023 51,000.00
Dec 31, 2022 50,000.00
Sep 30, 2022 49,000.00
Jun 30, 2022 91,000.00
Mar 31, 2022 67,000.00
Sep 30, 2021 74,000.00
Jun 30, 2021 61,000.00
Mar 31, 2021 55,000.00
Sep 30, 2020 38,000.00
Jun 30, 2020 33,000.00